[Comparison between AngII receptor antagonist and ACE inhibitor].

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Renal Physiology

Background:

• Angiotensin II (AII) significantly accelerates cardiovascular diseases.
• Blockade of the renin-angiotensin system (RAS) demonstrates clinical benefits in cardiovascular patients.
• Understanding the distinct mechanisms of RAS inhibitors is crucial for effective treatment.

Purpose of the Study:

• To compare Angiotensin II (AII) receptor antagonists and ACE inhibitors.
• To elucidate differences in basic and clinical aspects of these drug classes.
• To inform clinical decision-making based on distinct pharmacological profiles.

Main Methods:

• Comparative review of existing literature on AT1-receptor antagonists and ACE inhibitors.
• Analysis of effects on Angiotensin II (AII) and bradykinin concentrations.
• Evaluation of clinical outcomes and side effect profiles.

Main Results:

• ACE inhibitors decrease AII and increase bradykinin, potentially causing cough.
• AII receptor antagonists increase AII, which may affect drug binding and stimulate AT2 receptors.
• ACE inhibitors do not block non-ACE mediated AII formation, unlike AII receptor antagonists.

Conclusions:

• Distinct mechanisms of ACE inhibitors and AII receptor antagonists necessitate careful clinical consideration.
• Bradykinin-mediated effects and non-ACE AII formation are key differentiating factors.
• Tailoring RAS blockade therapy based on these differences can optimize patient outcomes.